Kay Stubenrauch
Roche (Switzerland)(CH)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Biosimilars and Bioanalytical Methods, Angiogenesis and VEGF in Cancer, Protein purification and stability, Glycosylation and Glycoproteins Research
Most-Cited Works
- → Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies(2011)462 cited
- → Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival(2016)351 cited
- → Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases(2016)342 cited
- → Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies(2012)199 cited
- → Low immunogenicity of tocilizumab in patients with rheumatoid arthritis(2016)101 cited
- → First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors(2017)99 cited
- → 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 – Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62)(2019)92 cited
- → Quality Requirements for Critical Assay Reagents Used in Bioanalysis of Therapeutic Proteins: What Bioanalysts Should Know About Their Reagents(2011)76 cited
- → Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing(2010)70 cited
- → 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( Part 3 –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)(2021)60 cited